https://orcid.org/0000-0001-7279-2156
References
- Boehm U, Bouloux PM, Dattani MT, et al. Expert consensus document: European consensus statement on congenital hypogonadotropic hypogonadism-pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2015;11(9):547–564.
- Vasques GA, Funari MFA, Ferreira FM, et al. IHH gene mutations causing short stature with nonspecific skeletal abnormalities and response to growth hormone therapy. J Clin Endocrinol Metab. 2018;103(2):604–614.
- Gharib SD, Wierman ME, Shupnik MA, et al. Molecular biology of the pituitary gonadotropins. Endocr Rev. 1990;11(1):177–199.
- Stamou MI, Georgopoulos NA. Kallmann syndrome: phenotype and genotype of hypogonadotropic hypogonadism. Metabolism. 2018;86:124–134.
- Topaloğlu AK. Update on the genetics of idiopathic hypogonadotropic hypogonadism. J Clin Res Pediatr Endocrinol. 2017;9(Suppl 2):113–122.
- Bhagavath B, Layman LC. The genetics of hypogonadotropic hypogonadism. Semin Reprod Med. 2007;25(4):272–286.
- Bianco SD, Kaiser UB. The genetic and molecular basis of idiopathic hypogonadotropic hypogonadism. Nat Rev Endocrinol. 2009;5(10):569–576.
- Young J, Xu C, Papadakis GE, et al. Clinical management of congenital hypogonadotropic hypogonadism. Endocr Rev. 2019;40(2):669–710.
- Meczekalski B, Podfigurna-Stopa A, Smolarczyk R, et al. Kallmann syndrome in women: from genes to diagnosis and treatment. Gynecol Endocrinol. 2013;29(4):296–300.
- Gill JC, Moenter SM, Tsai PS. Developmental regulation of gonadotropin-releasing hormone neurons by fibroblast growth factor signaling. Endocrinology. 2004;145(8):3830–3839.
- Latko M, Czyrek A, Porębska N, et al. Cross-Talk between fibroblast growth factor receptors and other cell surface proteins. Cells. 2019;8(5):455.
- Tsai PS, Brooks LR, Rochester JR, et al. Fibroblast growth factor signaling in the developing neuroendocrine hypothalamus. Front Neuroendocrinol. 2011;32(1):95–107.
- Thurman RD, Kathir KM, Rajalingam D, et al. Molecular basis for the kallmann syndrome-linked fibroblast growth factor receptor mutation. Biochem Biophys Res Commun. 2012;425(3):673–678.
- Raivio T, Sidis Y, Plummer L, et al. Frequency of impaired fibroblast growth factor receptor 1 signaling as a cause of normosmic idiopathic hypogonadotropic hypogonadism. Endocr Rev. 2009;30(7):934.
- Sönmezer M, Özmen B, Atabekoglu CS, et al. Serum anti-Mullerian hormone levels correlate with ovarian response in idiopathic hypogonadotropic hypogonadism. J Assist Reprod Genet. 2012;29(7):597–602.
- Bry-Gauillard H, Larrat-Ledoux F, Levaillant JM, et al. Anti-Müllerian hormone and ovarian morphology in women with isolated hypogonadotropic hypogonadism/kallmann syndrome: Effects of recombinant human FSH. J Clin Endocrinol Metab. 2017;102(4):1102–1111.